Skip to main content
Arcellx, Inc. logo

Arcellx, Inc. — Investor Relations & Filings

Ticker · ACLX ISIN · US03940C1009 US Manufacturing
Filings indexed 411 across all filing types
Latest filing 2024-02-09 Regulatory Filings
Country US United States of America
Listing US ACLX

About Arcellx, Inc.

https://www.arcellx.com/

Arcellx, Inc. is a clinical-stage biotechnology company that develops immunotherapies for patients with cancer and autoimmune diseases. The company is focused on reimagining cell therapy through its proprietary D-Domain technology. This technology is the foundation for its two main platforms: ddCAR, which produces autologous and allogeneic CAR-T therapies, and ARC-SparX, which involves controllable and adaptable cell therapies. Arcellx's lead investigational product, CART-ddBCMA, is in clinical development for the treatment of relapsed or refractory multiple myeloma. The company aims to create therapies that are safer, more effective, and more broadly accessible.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-02-09 English
8-K
Regulatory Filings
2024-01-31 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-01-29 English
FORM 4 SUBMISSION
Director's Dealing
2024-01-08 English
FORM 4 SUBMISSION
Director's Dealing
2024-01-08 English
FORM 4 SUBMISSION
Director's Dealing
2024-01-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.